Literature DB >> 21107627

Calcineurin-dependent galactomannan release in Aspergillus fumigatus.

M A S H Mennink-Kersten1, D Ruegebrink, P E Verweij, W J Steinbach.   

Abstract

The galactomannan assay to diagnose invasive aspergillosis is recommended and clinically utilized, yet the mechanism of galactomannan release from Aspergillus fumigatus is unknown. We used an A. fumigatus strain lacking calcineurin A (cnaA), already shown to be critically important for pathogenicity, to evaluate galactomannan kinetics. During the logarithmic growth phase when glucose was consumed, β-D-galactofuranoside (galf)-antigens were released in the culture. However, after glucose became limited, GM release further increased in the supernatants of the wild type strain while there was no further increase of GM release in the ΔcnaA strain. β-Galactofuranosidase activity was also decreased in the ΔcnaA mutant, and the amount of galf-antigen in the cell wall fraction of the ΔcnaA mutant was approximately ten-fold higher. This suggests the possibility that the antigen is unable to be released due to a cell wall abnormality. This and previous work suggest a dynamic calcineurin-dependent cell wall during periods of growth, with galactomannan release from the cell wall possibly calcineurin-dependent and reflected in the decreased GM release and greatly increased cell wall fraction of galf in the ΔcnaA mutant.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21107627     DOI: 10.1007/s10096-010-1118-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  7 in total

1.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

2.  Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus.

Authors:  William J Steinbach; Robert A Cramer; B Zachary Perfect; Yohannes G Asfaw; Theodor C Sauer; Laura K Najvar; William R Kirkpatrick; Thomas F Patterson; Daniel K Benjamin; Joseph Heitman; John R Perfect
Journal:  Eukaryot Cell       Date:  2006-07

3.  In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis.

Authors:  Monique A S H Mennink-Kersten; Dorien Ruegebrink; Nazhat Wasei; Willem J G Melchers; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

4.  Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus.

Authors:  J P Latgé; H Kobayashi; J P Debeaupuis; M Diaquin; J Sarfati; J M Wieruszeski; E Parra; J P Bouchara; B Fournet
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

5.  Antigens of Aspergillus fumigatus produced in vivo.

Authors:  J Sarfati; D G Boucias; J P Latgé
Journal:  J Med Vet Mycol       Date:  1995 Jan-Feb

Review 6.  Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections.

Authors:  William J Steinbach; Jennifer L Reedy; Robert A Cramer; John R Perfect; Joseph Heitman
Journal:  Nat Rev Microbiol       Date:  2007-06       Impact factor: 60.633

7.  Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus.

Authors:  William J Steinbach; Robert A Cramer; B Zachary Perfect; Christina Henn; Kirsten Nielsen; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

  7 in total
  1 in total

1.  Addition of 17-(allylamino)-17-demethoxygeldanamycin to a suboptimal caspofungin treatment regimen in neutropenic rats with invasive pulmonary aspergillosis delays the time to death but does not enhance the overall therapeutic efficacy.

Authors:  Jeannine M Refos; Alieke G Vonk; Marian T Ten Kate; Kimberly Eadie; Henri A Verbrugh; Irma A J M Bakker-Woudenberg; Wendy W J van de Sande
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.